INT207202

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.16
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 10
Total Number 10
Disease Relevance 1.76
Pain Relevance 1.71

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transport (Gopc) Golgi apparatus (Gopc) plasma membrane (Gopc)
cytoplasm (Gopc)
Anatomy Link Frequency
skeletal muscle 4
astrocytes 2
Gopc (Mus musculus)
Pain Link Frequency Relevance Heat
antagonist 233 96.60 Very High Very High Very High
Hippocampus 19 89.96 High High
chronic construction injury 29 86.56 High High
depression 10 80.32 Quite High
Neuropeptide 1 71.36 Quite High
Inflammation 58 50.00 Quite Low
antidepressant 32 50.00 Quite Low
allodynia 26 50.00 Quite Low
calcitonin gene related peptide 6 36.08 Quite Low
nociceptor 2 28.32 Quite Low
Disease Link Frequency Relevance Heat
Injury 66 100.00 Very High Very High Very High
Embryonal Carcinoma 46 90.00 High High
Stress 69 85.04 High High
Depression 14 80.32 Quite High
Nervous System Injury 21 75.40 Quite High
INFLAMMATION 60 50.00 Quite Low
Neuropathic Pain 49 50.00 Quite Low
Targeted Disruption 29 50.00 Quite Low
Body Weight 5 40.96 Quite Low
Nociception 16 36.44 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
However, similar to TRPM8 and TRPA1, this mRNA was also expressed at a lower level after injury (Fig. 2d).
Positive_regulation (level) of Transcription (expressed) of Fig associated with injury
1) Confidence 0.16 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2753652 Disease Relevance 0.87 Pain Relevance 0.16
To ensure that the promoter was still able to confer stimulus-dependent luciferase gene transcription, vibratome slices of CRE-Luc mice were incubated with 10 µM forskolin to induce CRE/CREB-directed transcription (Fig. 3C).
Positive_regulation (induce) of Transcription (transcription) of Fig
2) Confidence 0.16 Published 2007 Journal PLoS ONE Section Body Doc Link PMC1855984 Disease Relevance 0.38 Pain Relevance 0.11
B inhibitor pyrrolidine dithiocarbamate (20), the NFAT-specific inhibitory 3,5-bistrifluoromethyl pyrazole derivative BTP1 (21), and the calcineurin-inhibitor cyclosporine A (22) all blocked the PMA/ionomycin-induced expression of twist1 mRNA (Fig. 3 B), showing that both NFAT and NF-?
Positive_regulation (induced) of Transcription (expression) of Fig
3) Confidence 0.16 Published 2008 Journal The Journal of Experimental Medicine Section Body Doc Link PMC2525589 Disease Relevance 0 Pain Relevance 0
PLD4 mRNA expression was also distinguishable from glial fibrillary acidic protein (GFAP) mRNA expression in astrocytes (Fig. 4B-c, c', d and d'), neural stem cells, and radial glia in the SVZ (Fig. 4-d and d').
Positive_regulation (distinguishable) of Transcription (expression) of Fig in astrocytes
4) Confidence 0.16 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2978679 Disease Relevance 0 Pain Relevance 0
As shown in Figures 6C and 6D, treatment also induced the mRNA genes involved in skeletal muscle morphogenesis, myogenin mRNA (Fig. 6C) and MyoD mRNA (Fig. 6D).
Positive_regulation (induced) of Transcription (involved) of Fig in skeletal muscle
5) Confidence 0.13 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2964328 Disease Relevance 0.26 Pain Relevance 0.04
As shown in Figures 6C and 6D, treatment also induced the mRNA genes involved in skeletal muscle morphogenesis, myogenin mRNA (Fig. 6C) and MyoD mRNA (Fig. 6D).
Positive_regulation (induced) of Transcription (involved) of Fig in skeletal muscle
6) Confidence 0.13 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2964328 Disease Relevance 0.26 Pain Relevance 0.04
caused a significant time-dependent increase in COX-2 Luciferase reporter activity (Fig, 4A; P < 0.05) and mRNA expression (Fig. 4B; P < 0.05) which peaked at 4–6 h.
Positive_regulation (caused) of Transcription (expression) of Fig
7) Confidence 0.03 Published 2008 Journal Molecular and Cellular Endocrinology Section Body Doc Link PMC2694994 Disease Relevance 0 Pain Relevance 0.31
-induced elevation in COX-2 Luciferase (Fig. 5C) and mRNA expression (Fig. 5D) was significantly inhibited by co-treatment of cells with the FP receptor antagonist (AL8810), and chemical inhibitors of PLC (U73122), PKA (4C3MQ), EGFR kinase (AG1478) and ERK1/2 kinase (PD98059), but not the EP2 receptor antagonist (AH6809), EP4 receptor antagonist (ONOAE2227) or PKC inhibitor (GF109203x; Fig. 5C and D, P < 0.05).


Positive_regulation (elevation) of Transcription (expression) of Fig associated with antagonist
8) Confidence 0.03 Published 2008 Journal Molecular and Cellular Endocrinology Section Body Doc Link PMC2694994 Disease Relevance 0 Pain Relevance 0.37
caused a significant time-dependent increase in COX-2 Luciferase reporter activity (Fig, 4A; P < 0.05) and mRNA expression (Fig. 4B; P < 0.05) which peaked at 4–6 h.
Positive_regulation (increase) of Transcription (expression) of Fig
9) Confidence 0.03 Published 2008 Journal Molecular and Cellular Endocrinology Section Body Doc Link PMC2694994 Disease Relevance 0 Pain Relevance 0.30
-induced elevation in COX-2 Luciferase (Fig. 5C) and mRNA expression (Fig. 5D) was significantly inhibited by co-treatment of cells with the FP receptor antagonist (AL8810), and chemical inhibitors of PLC (U73122), PKA (4C3MQ), EGFR kinase (AG1478) and ERK1/2 kinase (PD98059), but not the EP2 receptor antagonist (AH6809), EP4 receptor antagonist (ONOAE2227) or PKC inhibitor (GF109203x; Fig. 5C and D, P < 0.05).


Positive_regulation (induced) of Transcription (expression) of Fig associated with antagonist
10) Confidence 0.03 Published 2008 Journal Molecular and Cellular Endocrinology Section Body Doc Link PMC2694994 Disease Relevance 0 Pain Relevance 0.37

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox